We treated, in a preliminary open trial, 31 patients presenting with cognitive impairment, progressive bilateral motor dysfunction, and leukoaraiosis on computed tomography (CT) with a 90-mg daily dose of nimodipine for a period as long as 1 year (minimum: 96 days, maximum: 424 days), to study the safety and possible effects on functional and cognitive conditions throughout this period. Of the 29 patients who had been followed for at least 9 months, most (82%) remained stable or improved as evaluated by the Global Deterioration Scale. A significant improvement was observed in the total Sandoz Clinical Assessment Geriatric scale score (44.66 +/- 7.17 at baseline vs. 36.86 +/- 9.34 at exit, analysis-of-variance time effect, p < 0.0001). These data indicate that nimodipine, chronically administered in patients presenting with cognitive impairment, progressive bilateral motor dysfunction, and leukoaraiosis on CT, is safe and might have beneficial effect, to be confirmed by a randomized trial.

A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis / L. Pantoni, M. Carosi, S. Amigoni, M. Mascalchi, D. Inzitari. - In: CLINICAL NEUROPHARMACOLOGY. - ISSN 0362-5664. - 19:6(1996 Dec), pp. 497-506.

A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis

L. Pantoni
;
1996-12

Abstract

We treated, in a preliminary open trial, 31 patients presenting with cognitive impairment, progressive bilateral motor dysfunction, and leukoaraiosis on computed tomography (CT) with a 90-mg daily dose of nimodipine for a period as long as 1 year (minimum: 96 days, maximum: 424 days), to study the safety and possible effects on functional and cognitive conditions throughout this period. Of the 29 patients who had been followed for at least 9 months, most (82%) remained stable or improved as evaluated by the Global Deterioration Scale. A significant improvement was observed in the total Sandoz Clinical Assessment Geriatric scale score (44.66 +/- 7.17 at baseline vs. 36.86 +/- 9.34 at exit, analysis-of-variance time effect, p < 0.0001). These data indicate that nimodipine, chronically administered in patients presenting with cognitive impairment, progressive bilateral motor dysfunction, and leukoaraiosis on CT, is safe and might have beneficial effect, to be confirmed by a randomized trial.
nimodipine; dementia; vascular dementia; leukoaraiosis; clinical trial
Settore MED/26 - Neurologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
A Preliminary Open Trial with Nimodipine.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 4.88 MB
Formato Adobe PDF
4.88 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/635563
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 36
social impact